middle.news
Vectus Converts VB4-P5 Sale into 9.9% Stake in XORTX Therapeutics
3:42pm on Thursday 30th of April, 2026 AEST
•
Healthcare
Read Story
Vectus Converts VB4-P5 Sale into 9.9% Stake in XORTX Therapeutics
3:42pm on Thursday 30th of April, 2026 AEST
Key Points
Sale of VB4-P5 to XORTX completed with equity consideration
Vectus holds 9.9% of XORTX plus pre-funded warrants
Ongoing licensing push for VB0004 and other fibrosis drugs
Operating costs trimmed with $130,000 spent in quarter
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vectus Biosystems (ASX:VBS)
OPEN ARTICLE